MDS Q4 losses include $320M write-down
MDS, a provider of products and services to the life sciences markets, has reported its final fourth quarter results following the completion of its year-end audit for the period that ended Oct. 31, 2008.
The final value of the MDS Pharma Services goodwill write-down is $320 million. The Toronto-based company reported a net loss of $575 million includes the goodwill write-down for MDS Pharma Services and the $246 million after-tax charge to write off the Maple asset.
For the fourth quarter of 2008, MDS reported total revenue of $322 million. Net revenue was $295 million and adjusted earnings before interest, taxes, depreciation and amortization was $36 million, compared with $307 million and $35 million in the prior year, respectively.
The final value of the MDS Pharma Services goodwill write-down is $320 million. The Toronto-based company reported a net loss of $575 million includes the goodwill write-down for MDS Pharma Services and the $246 million after-tax charge to write off the Maple asset.
For the fourth quarter of 2008, MDS reported total revenue of $322 million. Net revenue was $295 million and adjusted earnings before interest, taxes, depreciation and amortization was $36 million, compared with $307 million and $35 million in the prior year, respectively.